Daiichi Sankyo

Daiichi Sankyo is a global pharmaceutical company with its corporate origin in Japan.
read more ...

Corporate Governance Report has now been updated
read more ...

R&D Day 2019 material are now available.
read more ...

FY2019 Q2 financial results are now available.
read more ...

Completion of Payment Concerning Disposal of Treasury Shares as Restricted Share-Based Remuneration has been announced.
read more ...

2020.01.27	Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint
2020.01.07	ENHERTU® Now Available in U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2-Based Regimens
2019.12.23	ENHERTU® Approved in the U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2-Based Regimens
2019.12.19	Daiichi Sankyo Launches Antitumor Agent Bevacizumab Biosimilar for Intravenous Drip Infusions “Daiichi Sankyo” in Japan
2019.12.12	DS-8201 ([Fam-] Trastuzumab Deruxtecan) Achieved A Tumor Response Rate of 60.9% in Pivotal Phase 2 HER2 Positive Metastatic Breast Cancer Trial
2019.12.10	Daiichi Sankyo Initiates Pivotal Phase 2 Trial in Japan with Valemetostat in Patients with Adult T-Cell Leukemia-Lymphoma
2019.11.08	Daiichi Sankyo Announces Positive Results from ESAX-DN Phase 3 Study in Japan of Esaxerenone in Patients with Diabetic Nephropathy
2019.11.05	Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugate Technology

2019.12.10	Winners of 12th Manpei Suzuki International Prize for Diabetes Research and 13th Manpei Suzuki Prize for Diabetes Care and Education Announced
2019.06.20	Daiichi Sankyo’s Japan Research Foundation for Clinical Pharmacology 12th Annual Clinical Pharmacology Research Award
2019.02.14	Daiichi Sankyo supported World Cancer Day 2019
2018.12.06	Winners of 11th Manpei Suzuki International Prize for Diabetes Research and 12th Manpei Suzuki Prize for Diabetes Care and Education Announced